These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 26726123)

  • 1. Maternal serum soluble fms-like tyrosine kinase-1 at 22 and 32 weeks in the prediction of pre-eclampsia.
    Wright D; Krajewska K; Bogdanova A; Wright A; Nicolaides KH
    Ultrasound Obstet Gynecol; 2016 Jun; 47(6):755-61. PubMed ID: 26726123
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Maternal serum soluble fms-like tyrosine kinase-1 at 12, 22, 32 and 36 weeks' gestation in screening for pre-eclampsia.
    Tsiakkas A; Mendez O; Wright A; Wright D; Nicolaides KH
    Ultrasound Obstet Gynecol; 2016 Apr; 47(4):478-83. PubMed ID: 26582564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Competing-risks model in screening for pre-eclampsia by maternal factors and biomarkers at 35-37 weeks' gestation.
    Andrietti S; Silva M; Wright A; Wright D; Nicolaides KH
    Ultrasound Obstet Gynecol; 2016 Jul; 48(1):72-9. PubMed ID: 26566592
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of screening for pre-eclampsia at 31-34 weeks' gestation by sFlt-1/PlGF ratio and a method combining maternal factors with sFlt-1 and PlGF.
    Tan MY; Wright D; Koutoulas L; Akolekar R; Nicolaides KH
    Ultrasound Obstet Gynecol; 2017 Feb; 49(2):201-208. PubMed ID: 27671370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Longitudinal changes in maternal serum placental growth factor and soluble fms-like tyrosine kinase-1 in women at increased risk of pre-eclampsia.
    Khalil A; Maiz N; Garcia-Mandujano R; Penco JM; Nicolaides KH
    Ultrasound Obstet Gynecol; 2016 Mar; 47(3):324-31. PubMed ID: 26387758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 30-34 weeks' gestation.
    Tsiakkas A; Saiid Y; Wright A; Wright D; Nicolaides KH
    Am J Obstet Gynecol; 2016 Jul; 215(1):87.e1-87.e17. PubMed ID: 26875953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 19-24 weeks' gestation.
    Gallo DM; Wright D; Casanova C; Campanero M; Nicolaides KH
    Am J Obstet Gynecol; 2016 May; 214(5):619.e1-619.e17. PubMed ID: 26627730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of pre-eclampsia within 4 weeks of sFlt-1/PlGF ratio > 38: comparison of performance at 31-34 vs 35-37 weeks' gestation.
    Dragan I; Wright D; Fiolna M; Leipold G; Nicolaides KH
    Ultrasound Obstet Gynecol; 2017 Feb; 49(2):209-212. PubMed ID: 27671743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Screening for pre-eclampsia at 35-37 weeks' gestation.
    Panaitescu A; Ciobanu A; Syngelaki A; Wright A; Wright D; Nicolaides KH
    Ultrasound Obstet Gynecol; 2018 Oct; 52(4):501-506. PubMed ID: 29896778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proposed clinical management of pregnancies after combined screening for pre-eclampsia at 30-34 weeks' gestation.
    Wright D; Dragan I; Syngelaki A; Akolekar R; Nicolaides KH
    Ultrasound Obstet Gynecol; 2017 Feb; 49(2):194-200. PubMed ID: 27671544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Screening for pre-eclampsia using sFlt-1/PlGF ratio cut-off of 38 at 30-37 weeks' gestation.
    Dragan I; Georgiou T; Prodan N; Akolekar R; Nicolaides KH
    Ultrasound Obstet Gynecol; 2017 Jan; 49(1):73-77. PubMed ID: 27619203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of pregnancies after combined screening for pre-eclampsia at 19-24 weeks' gestation.
    Litwinska M; Syngelaki A; Wright A; Wright D; Nicolaides KH
    Ultrasound Obstet Gynecol; 2018 Sep; 52(3):365-372. PubMed ID: 29943498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proposed clinical management of pregnancies after combined screening for pre-eclampsia at 35-37 weeks' gestation.
    Panaitescu AM; Wright D; Militello A; Akolekar R; Nicolaides KH
    Ultrasound Obstet Gynecol; 2017 Sep; 50(3):383-387. PubMed ID: 28133834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of small-for-gestational-age neonates: screening by placental growth factor and soluble fms-like tyrosine kinase-1 at 35-37 weeks.
    Fadigas C; Peeva G; Mendez O; Poon LC; Nicolaides KH
    Ultrasound Obstet Gynecol; 2015 Aug; 46(2):191-7. PubMed ID: 25825848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive value of angiogenic factors, clinical risk factors and uterine artery Doppler for pre-eclampsia and fetal growth restriction in second and third trimester pregnancies in an Ecuadorian population.
    Kienast C; Moya W; Rodriguez O; Jijón A; Geipel A
    J Matern Fetal Neonatal Med; 2016; 29(4):537-43. PubMed ID: 25708492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Repeat measurements of uterine artery pulsatility index, mean arterial pressure and serum placental growth factor at 12, 22 and 32 weeks in prediction of pre-eclampsia.
    Andrietti S; Carlucci S; Wright A; Wright D; Nicolaides KH
    Ultrasound Obstet Gynecol; 2017 Aug; 50(2):221-227. PubMed ID: 28078815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of small-for-gestational-age neonates: screening by biophysical and biochemical markers at 30-34 weeks.
    Bakalis S; Peeva G; Gonzalez R; Poon LC; Nicolaides KH
    Ultrasound Obstet Gynecol; 2015 Oct; 46(4):446-51. PubMed ID: 25826154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum soluble fms-like tyrosine kinase-1 in the three trimesters of pregnancy: effects of maternal characteristics and medical history.
    Tsiakkas A; Duvdevani N; Wright A; Wright D; Nicolaides KH
    Ultrasound Obstet Gynecol; 2015 May; 45(5):584-90. PubMed ID: 25678265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Screening for pre-eclampsia by maternal serum glycosylated fibronectin and angiogenic markers at 36 weeks' gestation.
    Sokratous N; Wright A; Syngelaki A; Kakouri E; Laich A; Nicolaides KH
    Ultrasound Obstet Gynecol; 2024 Jan; 63(1):88-97. PubMed ID: 37724582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stratification of pregnancy care based on risk of pre-eclampsia derived from biophysical and biochemical markers at 19-24 weeks' gestation.
    Litwinska M; Litwinska E; Astudillo A; Syngelaki A; Wright A; Nicolaides KH
    Ultrasound Obstet Gynecol; 2021 Sep; 58(3):360-368. PubMed ID: 33794058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.